Noumed Life Sciences Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Noumed Life Sciences Limited Pharmaceutical Import Records from India — 3 Products, $3.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Noumed Life Sciences Limited — Pharmaceutical Importer Profile (2026) | 3 Products, $3.0M Trade | TransData Nexus

Noumed Life Sciences Limited

Pharmaceutical Importer · United Kingdom · Antihistamines & Allergy Focus · $3.0M Total Trade · DGFT Verified

Noumed Life Sciences Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $3.0M across 3 products in 3 therapeutic categories. Based on 70 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Noumed Life Sciences Limited sources from 6 verified Indian suppliers, with Fourrts (india) Laboratories Private Limited accounting for 40.4% of imports.

Noumed Life Sciences Limited — Import Portfolio & Supplier Network

Noumed Life Sciences Limited import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Noumed Life Sciences Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Fourrts (india) Laboratories Private Limited	$3.2M	134	40.4%
Fourrts India Laboratories Private Limited	$2.0M	73	24.8%
Lyrus Life Sciences Private Limited

What Formulations Does Noumed Life Sciences Limited Import?

Formulation	Value	Ships
Fexofenadine 180MG Film-Coated tablets	$650.0K	13
Naproxen 500MG	$411.0K	9
Sertraline 100MG	$183.7K	6
Fexofenadine 180MG Film-Coated tablets 30pack-product id	$177.7K	4
Sertraline 50MG	$173.1K	6
Propranolol 40MG	$168.8K	4
Erythromycin 250MG Gastro Resistant	$154.0K	4
Sertraline 50MG tablets 156339x2	$150.0K	3
Fexofenadine 180MG Film-Coated tablets 30 Pack product id	$132.0K	4
Fexofenadine 120MG Film-Coated tablets 30pack-product id	$130.2K	3
Metformin 500MG film coated	$128.3K	7
Ibuprofen dc granules 73%(krisoibu-73p)	$120.5K	3
Paracetamol capsules 500MG	$118.8K	6
Metformin 500MG flim coated	$107.5K	6
Naproxen 500MG tablets 78869x2	$100.0K	2

Noumed Life Sciences Limited imports 174 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fexofenadine	Antihistamines & Allergy	$2.1M	42	1.9%	11
2	Erythromycin	Antibiotics	$474.9K	12	0.6%	15
3	Propranolol	Cardiovascular	$435.6K	16	0.8%	9

Noumed Life Sciences Limited imports 3 pharmaceutical products across 3 categories into United Kingdom totaling $3.0M.

Noumed Life Sciences Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Noumed Life Sciences Limited is a privately held pharmaceutical manufacturing company headquartered in Maidenhead, Berkshire, United Kingdom. Established in 2013 and operational since 2016, Noumed specializes in the development, manufacturing, and marketing of a diverse range of high-quality generic pharmaceutical products. Their portfolio spans various therapeutic areas, aiming to enhance patient care through accessible and effective medications.

The company operates from Noumed House, located at Shoppenhangers Road, Maidenhead, SL6 2RB. This facility houses their manufacturing, packaging, and quality control operations, ensuring compliance with Good Manufacturing Practice (GMP) guidelines. Noumed's services include intellectual property licensing, manufacturing, and research and development, leveraging both in-house capabilities and global partnerships to meet market demands.

2Distribution Network

Noumed Life Sciences Limited's distribution network is centered around its Maidenhead facility, which serves as the primary hub for manufacturing, packaging, and quality control. The on-site warehouse is fully equipped to store materials requiring cold storage conditions and has dedicated areas for controlled substances, ensuring compliance with regulatory standards.

While specific details about additional warehouse locations or logistics capabilities are not publicly disclosed, Noumed's strategic location in Maidenhead provides convenient access to major transportation routes, facilitating efficient distribution across the United Kingdom and potentially to international markets. The company's commitment to quality and regulatory compliance underscores its ability to manage a robust distribution network.

3Industry Role

Noumed Life Sciences Limited plays a significant role in the United Kingdom's pharmaceutical supply chain as a pharmaceutical manufacturer. By developing and producing generic medications, Noumed contributes to increasing the availability of cost-effective treatment options within the UK market. Their focus on high-quality generics supports the healthcare system by providing alternatives to branded drugs, thereby enhancing patient access to essential therapies.

Additionally, Noumed's involvement in intellectual property licensing, manufacturing, and research and development indicates a comprehensive approach to pharmaceutical supply, encompassing both production and strategic partnerships to meet diverse market needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Noumed Life Sciences Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Noumed Life Sciences Limited's sourcing strategy reveals a high degree of concentration, with a total import value of $3.0 million USD from India over 70 shipments, primarily consisting of finished pharmaceutical formulations. The top three imported products—Fexofenadine, Erythromycin, and Propranolol—account for 69.8%, 15.8%, and 14.5% of the total import value, respectively. This indicates a focused product portfolio, with these three products comprising 100% of the company's imports from India.

The reliance on a limited number of products suggests a strategic choice to concentrate on high-demand medications within specific therapeutic categories. However, this concentration also exposes Noumed to potential supply chain risks, such as disruptions from Indian suppliers or fluctuations in product demand. The stability of their supplier relationships is crucial, as evidenced by the significant import values from suppliers like FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED ($3.2 million, 40.4% of total imports) and FOURRTS INDIA LABORATORIES PRIVATE LIMITED ($2.0 million, 24.8%). The high dependency on these suppliers necessitates robust risk management strategies to mitigate potential disruptions.

2Supply Chain Resilience

Noumed Life Sciences Limited's supply chain resilience is closely tied to its sourcing strategy from India. The company's import data indicates a heavy reliance on a few key suppliers, with FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED and FOURRTS INDIA LABORATORIES PRIVATE LIMITED accounting for a combined 65.2% of total imports. This concentration could pose risks in the event of supply disruptions or changes in supplier performance.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing pharmaceutical imports. The MHRA is responsible for ensuring that medicines meet appropriate standards of safety, quality, and efficacy before they are marketed in the UK. (gov.uk)

Key legislation governing pharmaceutical imports includes the Medicines for Human Use (Clinical Trials) Regulations 2004 and the Human Medicines Regulations 2012. These regulations outline the requirements for importing, manufacturing, and distributing medicinal products within the UK. The MHRA's guidance on sourcing medicines provides detailed information on the importation process, including licensing requirements and compliance with Good Manufacturing Practice (GMP). (gov.uk)

2Import Licensing & GMP

To import human medicines into the UK, companies must obtain a Wholesale Distribution Licence (WDA(H)) and, if applicable, a Manufacturer's Licence. Additionally, a Marketing Authorisation (MA) is required for each medicinal product to be marketed. These licences ensure that imported medicines meet the necessary standards for safety, quality, and efficacy. (gov.uk)

The MHRA recognizes GMP certificates from various authorities, including the European Union (EU), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certificates from recognized authorities to comply with UK regulations. (gov.uk)

Noumed Life Sciences Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Noumed Life Sciences Limited's focus on importing finished pharmaceutical formulations from India, particularly in the therapeutic categories of Antihistamines & Allergy, Antibiotics, and Cardiovascular, aligns with market demand for cost-effective and accessible treatments in these areas. The top three imported products—Fexofenadine, Erythromycin, and Propranolol—are widely used medications, indicating a strategic approach to meet prevalent health concerns in the UK.

The company's concentrated product portfolio suggests a deliberate strategy to specialize in high-demand therapeutic areas, potentially enhancing expertise and competitiveness in these segments. This focus allows Noumed to streamline operations and maintain quality standards across a select range of products.

2Sourcing Profile

Noumed Life Sciences Limited's sourcing strategy emphasizes importing finished pharmaceutical formulations from India, leveraging the country's established manufacturing capabilities and cost advantages. The company's focus on specific therapeutic categories indicates a targeted approach to meet market needs. By maintaining a concentrated product portfolio, Noumed can ensure quality control and regulatory compliance, which are critical in the pharmaceutical industry.

3Market Positioning

Seller's Guide — How to Become a Supplier to Noumed Life Sciences Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Noumed Life Sciences Limited, especially if they can offer products that align with Noumed's therapeutic focus and meet the required quality standards.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Noumed Life Sciences Limited

What products does Noumed Life Sciences Limited import from India?

Noumed Life Sciences Limited imports 3 pharmaceutical products across 3 categories. Top imports: Fexofenadine ($2.1M), Erythromycin ($474.9K), Propranolol ($435.6K).

Who supplies pharmaceuticals to Noumed Life Sciences Limited from India?

Noumed Life Sciences Limited sources from 6 verified Indian suppliers. The primary supplier is Fourrts (india) Laboratories Private Limited (40.4% of imports, $3.2M).

What is Noumed Life Sciences Limited's total pharmaceutical import value?

Noumed Life Sciences Limited's total pharmaceutical import value from India is $3.0M, based on 70 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Noumed Life Sciences Limited focus on?

Noumed Life Sciences Limited imports across 3 categories. The largest: Antihistamines & Allergy (69.8%), Antibiotics (15.8%), Cardiovascular (14.5%).

Get Full Noumed Life Sciences Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.